Abbott Laboratories
Abbott Laboratories (ABT) is a diversified global healthcare company operating across diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. With a market capitalisation around $221.98B, Abbott supplies a mix of recurring-revenue products — from diagnostic systems and cardiovascular devices to glucose-monitoring products and infant nutrition — that can offer relative resilience across economic cycles. Investors should note its exposure to regulatory approvals, reimbursement policies and competition from large medtech and pharmaceutical peers, plus currency and supply-chain risks in international markets. Abbott invests in R&D and product upgrades, which can support long-term growth but also requires ongoing capital. The company has historically returned cash to shareholders, yet past distributions do not guarantee future payments. This summary is for general, educational purposes and is not personalised investment advice; individuals should assess suitability, consult up-to-date sources, and consider seeking regulated financial advice before investing.
Why It's Moving
ABT Gains Traction as Insider Buys Signal Confidence Amid Medical Device Momentum
- Director Daniel Starks bought nearly 10,000 shares worth over $1 million on February 4, reinforcing belief in ABT's undervalued position as it trades near its yearly low.
- Volt Pulsed Field Ablation System posted 84.2% success in paroxysmal AF cases at the AF Symposium, signaling edge over rivals with fewer applications needed.
- Mixed analyst reactions post-Q4 results highlight Nutrition challenges but praise Exact Sciences deal and device catalysts like TriClip coverage for 2026 recovery.
ABT Gains Traction as Insider Buys Signal Confidence Amid Medical Device Momentum
- Director Daniel Starks bought nearly 10,000 shares worth over $1 million on February 4, reinforcing belief in ABT's undervalued position as it trades near its yearly low.
- Volt Pulsed Field Ablation System posted 84.2% success in paroxysmal AF cases at the AF Symposium, signaling edge over rivals with fewer applications needed.
- Mixed analyst reactions post-Q4 results highlight Nutrition challenges but praise Exact Sciences deal and device catalysts like TriClip coverage for 2026 recovery.
When is the next earnings date for Abbott Laboratories (ABT)?
Abbott Laboratories (ABT) is scheduled to report its next earnings on January 22, 2026, covering the fiscal quarter ending December 2025. This date aligns with the company's historical pattern of releasing Q4 results in late January, as confirmed across multiple analyst estimates. Investors should monitor for any official updates from the company, typically issued after market close or pre-market.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Abbott Laboratories' stock with a target price of $145.11, indicating growth potential.
Financial Health
Abbott Laboratories is earning substantial revenue and profits, showing strong financial stability and cash flow.
Dividend
Abbott Laboratories' average dividend yield of 2.2% provides a modest return for dividend investors. If you invested $1000 you would be paid $22 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ABT
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: September 23, 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: September 22, 2025
Explore BasketDiagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: July 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Stable revenue mix
Recurring sales from diagnostics and devices can support steadier cash flows, though performance will vary and is not guaranteed.
Global market reach
A broad international footprint offers growth opportunities but brings currency, regulatory and supply-chain exposure to watch.
Product innovation focus
Ongoing R&D and device upgrades can drive long-term growth, yet new product development faces regulatory and competitive hurdles.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Avantor Inc
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
